COMP360 is the first classic psychedelic 1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profile In ...

George Goldsmith is the Chairman, CEO and Co‑Founder of COMPASS Pathways (NASDAQ:CMPS). Mr. Goldsmith’s early training and experience was a multi-disciplinary blending of cognitive psychology, ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

A synthetic form of the active ingredient in magic mushrooms has cleared an early-phase trial. The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any ...

Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the millions of patients who have cycled through multiple antidepressants ...